BioSpace News Archive

Dynamic Technology Solutions (Dynamic) announced today the introduction of its EOL PrepSM Self-Diagnostic, based on industry best practices, that provides insights into how well a company is managing risks associated with product End-of-Life (EOL).

Evolus, Inc. today announced its preliminary, unaudited net revenue and cash position as of and for the fourth quarter and full-year ended December 31, 2021.

Checkpoint Surgical, Inc., the leader in intraoperative nerve repair stimulation technology, today announced it has enrolled the first patient in its multi-center clinical study of the company’s breakthrough nerve regeneration technology.

Research published by Oregon Health & Science University and Indiana University in the Journal of Pediatrics reports on administering a specific gut bacterium, Bifidobacterium longum infantis EVC001 relative to the standard of care for very low birth weight infants in a single Level IV NICU.

Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology.

Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that it is starting a “Compassionate Use Clinical Trial” for treatment of Parkinson’s disease.

Laser Medical Canada of Laval, Quebec, has pleaded guilty to charges related to illegally selling and advertising unlicensed medical devices, providing false statements to Health Canada inspectors, and interfering with seized products.

South Carolina’s Integrated Micro-Chromatography Systems, Inc. (IMCS), a leader in recombinant enzymes and micro-chromatography technologies, was awarded $1.8 million for Phase II of its Fast-Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health/ National Institute of General Medical Sciences (NIH/NIGMS).

ACCUMTM is an enabling technology as it can be used to enhance the intracellular accumulation of various proteins of pharmacological interests into any target cells.

Polaris Pharmaceuticals, Inc. Vacaville has purchased 15 acres in the City of Vacaville’s Vaca Valley Business Park, a transaction that represents another advancement in the City’s plans to expand its biotechnology footprint and solidify itself as a global center for biomanufacturing.